



FOR IMMEDIATE RELEASE

Prime Synthesis, Inc. receives SBIR Grant from the NIH

(Aston, Pennsylvania, April 2, 2009) – Prime Synthesis, Inc. announced today that it received a \$100,000 Phase I Small Business Innovative Research Grant from the National Institute of General Medical Sciences division of the National Institutes of Health.

The grant was awarded for a research proposal entitled “**A Novel Hybrid Solid Support for Cost-Effective, Large-Scale Oligonucleotide Synthesis**”. In this proposal the company will develop a new generation of products to reduce the costs and improve purity and yields of oligonucleotide synthesis. This will enable the new class of drugs based on synthetic DNA and RNA fragments (oligonucleotides) to be more effectively and economically produced. Nearly 150 new drugs, based on this technology are currently in clinical trials, many addressing such important areas as cancer and various cardiac disorders.

“Over the past decade, we have supplied a key raw material for the production of this exciting new class of drugs” said Marc Rothstein, President of Prime Synthesis. “As the pharmaceutical industry moves closer to commercial products based on this technology, the need for lower cost, high volume manufacture becomes more important. Our research efforts, funded in part by this grant, will allow us to address this need with innovative new products.

About Prime Synthesis, Inc.

Prime Synthesis, Inc., located in Aston, Pa., supplies products and services to oligonucleotide researchers for DNA and RNA synthesis. Its product lines include controlled porosity glass (CPG) in standard and customized chemical formats, synthesis columns, and column parts. For more information on Prime Synthesis’ full line of products and services or to purchase these products, visit their e-commerce site at www.primesynthesis.com

Contact: Marc Rothstein
President, Prime Synthesis, Inc.
mlrothstein@primesynthesis.com
www.primesynthesis.com